CA2703672A1 - Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction - Google Patents

Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction Download PDF

Info

Publication number
CA2703672A1
CA2703672A1 CA2703672A CA2703672A CA2703672A1 CA 2703672 A1 CA2703672 A1 CA 2703672A1 CA 2703672 A CA2703672 A CA 2703672A CA 2703672 A CA2703672 A CA 2703672A CA 2703672 A1 CA2703672 A1 CA 2703672A1
Authority
CA
Canada
Prior art keywords
fluid
ppm
membrane
rotor
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703672A
Other languages
English (en)
French (fr)
Inventor
Richard L. Watson
Anthony B. Wood
Gregory J. Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Application filed by Individual filed Critical Individual
Publication of CA2703672A1 publication Critical patent/CA2703672A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
CA2703672A 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction Abandoned CA2703672A1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
US60/982,719 2007-10-25
USPCT/US2007/082581 2007-10-25
USPCT/US2007/082580 2007-10-25
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
US60/982,720 2007-10-25
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
USPCT/US2007/082578 2007-10-25
US4834008P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US61/048,404 2008-04-28
US61/048,340 2008-04-28
US61/048,347 2008-04-28
US61/048,332 2008-04-28
PCT/US2008/081021 WO2009055614A1 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Publications (1)

Publication Number Publication Date
CA2703672A1 true CA2703672A1 (en) 2009-04-30

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2703672A Abandoned CA2703672A1 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
CA2703739A Abandoned CA2703739A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis
CA2703754A Active CA2703754C (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2703739A Abandoned CA2703739A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis
CA2703754A Active CA2703754C (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation

Country Status (8)

Country Link
EP (3) EP2215260A4 (https=)
JP (6) JP5613565B2 (https=)
CN (5) CN101910412B (https=)
AU (3) AU2008316794B2 (https=)
CA (3) CA2703672A1 (https=)
IL (3) IL205319A (https=)
MX (3) MX2010004563A (https=)
WO (1) WO2009055614A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
CA2741336A1 (en) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
AU2010241736B2 (en) * 2009-04-27 2016-01-28 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) * 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
KR20130100126A (ko) * 2010-08-13 2013-09-09 레발레시오 코퍼레이션 심혈관 질환을 치료하기 위한 조성물 및 방법
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
JP6368459B2 (ja) * 2012-06-14 2018-08-01 松本　高明 点眼液の製造方法
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
CA3064050A1 (en) * 2017-05-23 2018-11-29 Biovite Australia Pty Ltd. Extracts from arthrospira and uses thereof
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
EP1100811B1 (en) * 1998-07-28 2007-07-04 The Regents Of The University Of California Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
EP1237578A4 (en) * 1999-10-26 2004-10-27 Bio Hydration Res Lab Inc MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
WO2002024222A2 (en) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
EP1357920B1 (en) * 2001-02-01 2007-09-05 Hydron Technologies Inc. Compositions and method of tissue superoxygenation
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
US20060073212A1 (en) * 2004-04-22 2006-04-06 Palmer Craig R Method of treating respiratory disorders and airway inflammation
AU2005329764B2 (en) * 2005-03-28 2010-08-12 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
EP1901749B1 (en) * 2005-05-18 2016-08-03 Raptor Pharmaceuticals Inc. Aerosolized fluoroquinolones and uses thereof
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION

Also Published As

Publication number Publication date
EP2215260A1 (en) 2010-08-11
EP2224924A4 (en) 2011-01-12
CN101909648A (zh) 2010-12-08
AU2008316663A1 (en) 2009-04-30
CN103933567A (zh) 2014-07-23
IL205319A (en) 2016-06-30
AU2008316623B2 (en) 2015-01-22
JP2011500844A (ja) 2011-01-06
IL205319A0 (en) 2010-12-30
CN104771758A (zh) 2015-07-15
EP2214707A1 (en) 2010-08-11
JP5911197B2 (ja) 2016-04-27
JP2014169328A (ja) 2014-09-18
CN101909623A (zh) 2010-12-08
MX2010004564A (es) 2010-07-28
EP2214707B1 (en) 2017-07-12
EP2224924A1 (en) 2010-09-08
JP2014193915A (ja) 2014-10-09
CN101909623B (zh) 2015-04-01
CN101909648B (zh) 2014-04-16
JP2014205693A (ja) 2014-10-30
AU2008316663B2 (en) 2014-12-18
CA2703754A1 (en) 2009-04-30
JP2011500847A (ja) 2011-01-06
JP5613565B2 (ja) 2014-10-22
JP2011500837A (ja) 2011-01-06
IL205317A0 (en) 2010-12-30
IL205317A (en) 2016-03-31
EP2214707A4 (en) 2011-04-20
CA2703754C (en) 2019-04-09
JP5869763B2 (ja) 2016-02-24
IL205318A0 (en) 2010-12-30
IL205318A (en) 2017-01-31
EP2215260A4 (en) 2011-04-20
CA2703739A1 (en) 2009-04-30
MX2010004554A (es) 2010-07-28
AU2008316623A1 (en) 2009-04-30
CN101910412A (zh) 2010-12-08
MX2010004563A (es) 2010-07-28
AU2008316794B2 (en) 2015-04-23
AU2008316794A1 (en) 2009-04-30
WO2009055614A1 (en) 2009-04-30
CN101910412B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
AU2008316794B2 (en) Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090227018A1 (en) Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100029764A1 (en) Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090263495A1 (en) Bacteriostatic or bacteriocidal compositions and methods
EP2214712B1 (en) Compositions and methods for treating asthma and lung disorders
US20100303871A1 (en) Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100009008A1 (en) Bacteriostatic or bacteriocidal compositions and methods
US20100310665A1 (en) Bacteriostatic or bacteriocidal compositions and methods
AU2014200002B2 (en) Bacteriostatic or bacteriocidal compositions and methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131002

FZDE Discontinued

Effective date: 20171024